See more : THK Co., Ltd. (THKLF) Income Statement Analysis – Financial Results
Complete financial analysis of Perspective Therapeutics, Inc. (CATX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Perspective Therapeutics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Acsion Limited (ACS.JO) Income Statement Analysis – Financial Results
- Croda International Plc (49GP.L) Income Statement Analysis – Financial Results
- Fibra Danhos (GRFFF) Income Statement Analysis – Financial Results
- ReNeuron Group plc (RNUGF) Income Statement Analysis – Financial Results
- Kim Heng Limited (5G2.SI) Income Statement Analysis – Financial Results
Perspective Therapeutics, Inc. (CATX)
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.43M | 7.10M | 10.80M | 10.05M | 9.68M | 7.31M | 5.92M | 4.76M | 4.77M | 4.61M | 4.22M | 4.53M | 5.07M | 5.24M | 5.29M | 5.42M | 7.16M | 5.74M | 1.99M | 201.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.85M | 8.26M | 7.82M | 6.79M |
| Cost of Revenue | 0.00 | 5.47M | 6.18M | 4.93M | 4.56M | 4.27M | 4.08M | 3.92M | 4.64M | 4.44M | 4.42M | 4.38M | 4.37M | 4.08M | 4.56M | 5.77M | 7.31M | 5.79M | 3.82M | 1.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.68M | 7.46M | 6.99M | 6.42M |
| Gross Profit | 1.43M | 1.63M | 4.62M | 5.12M | 5.12M | 3.05M | 1.84M | 838.00K | 129.15K | 167.39K | -196.47K | 150.18K | 703.20K | 1.16M | 725.80K | -353.33K | -151.43K | -54.60K | -1.82M | -1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.16M | 795.61K | 822.28K | 367.89K |
| Gross Profit Ratio | 100.00% | 23.00% | 42.76% | 50.94% | 52.93% | 41.66% | 31.10% | 17.60% | 2.71% | 3.63% | -4.66% | 3.32% | 13.87% | 22.09% | 13.73% | -6.52% | -2.12% | -0.95% | -91.30% | -630.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14.84% | 9.63% | 10.52% | 5.42% |
| Research & Development | 21.31M | 2.60M | 2.58M | 1.43M | 1.13M | 1.47M | 1.75M | 965.00K | 528.05K | 614.77K | 668.80K | 627.11K | 730.58K | 465.33K | 340.96K | 958.67K | 1.36M | 1.35M | 450.43K | 137.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 20.97M | 10.87M | 6.62M | 4.69M | 4.57M | 4.17M | 4.17M | 3.92M | 3.79M | 2.40M | 2.49M | 2.29M | 2.36M | 2.42M | 2.44M | 2.79M | 7.29M | 8.30M | 4.92M | 0.00 | 30.00K | 9.10K | 19.02K | 7.58K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 97.00K | 3.23M | 2.80M | 2.44M | 2.98M | 2.68M | 2.66M | 2.31M | 1.35M | 1.49M | 1.23M | 1.30M | 1.22M | 1.23M | 1.95M | 2.37M | 0.00 | 0.00 | 0.00 | 0.00 | -20.91K | 9.93K | -11.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 21.06M | 14.21M | 9.43M | 7.13M | 7.55M | 6.85M | 6.83M | 6.23M | 5.14M | 3.89M | 3.72M | 3.59M | 3.57M | 3.66M | 4.39M | 5.16M | 7.29M | 8.30M | 4.92M | 2.57M | 9.10K | 19.02K | 7.58K | 7.58K | 0.00 | 15.53K | 221.88K | 1.11M | 2.59M | 1.24M | 1.23M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -73.00K | 2.00K | 0.00 | -48.00K | -456.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.99K | 15.57K | 0.00 | 207.30K | 942.00 | 317.97K | 316.74K | 406.92K |
| Operating Expenses | 42.38M | 17.43M | 12.01M | 8.56M | 8.60M | 8.33M | 8.57M | 7.15M | 5.21M | 4.50M | 4.39M | 4.22M | 4.30M | 4.12M | 4.73M | 6.12M | 8.65M | 9.65M | 5.37M | 2.71M | 9.10K | 19.02K | 7.58K | 15.57K | 14.15K | 15.53K | 222.83K | 1.43M | 2.91M | 1.65M | 1.54M |
| Cost & Expenses | 42.38M | 22.90M | 18.19M | 13.49M | 13.16M | 12.59M | 12.65M | 11.07M | 9.85M | 8.94M | 8.81M | 8.59M | 8.67M | 8.20M | 9.29M | 11.89M | 15.96M | 15.44M | 9.19M | -4.18M | 9.10K | 19.02K | 7.58K | 15.57K | 14.15K | 15.53K | 222.83K | 8.11M | 10.37M | 8.64M | 7.96M |
| Interest Income | 934.00K | 1.12M | 119.00K | 59.00K | 30.00K | 108.00K | 29.00K | 118.00K | 218.15K | 282.75K | 12.11K | 664.00 | 747.00 | 3.38K | 11.43K | 111.05K | 0.00 | 0.00 | 0.00 | 2.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 84.00K | 0.00 | 119.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 950.00 | 2.21K | 883.00 | 7.00 | 61.68K | 216.61K | 36.39K | 75.31K | 274.00K | 0.00 | 1.02M | 167.49K | 0.00 | 2.10K | 41.01K | 51.50K | 0.00 | 0.00 | -12.44K | 0.00 | 163.27K | 66.96K | 108.63K |
| Depreciation & Amortization | 981.00K | 344.00K | 248.00K | 9.00K | 147.00K | -24.00K | 80.00K | 68.00K | 470.85K | 576.38K | 685.40K | 739.15K | 847.12K | 888.57K | 996.88K | 1.21M | 1.06M | 715.25K | 655.33K | 143.04K | 0.00 | 84.85K | -41.01K | -51.50K | 250.68K | -51.50K | 942.00 | 317.97K | 316.74K | 407.42K | 308.83K |
| EBITDA | -39.96M | -14.84M | -7.39M | -3.43M | -3.48M | -5.30M | -6.70M | -6.19M | -4.39M | -4.05M | -3.89M | -3.33M | -2.92M | -2.07M | -3.01M | -5.54M | -7.47M | -8.98M | -6.15M | -3.96M | -9.10K | -19.02K | -7.58K | -15.57K | -14.15K | -15.53K | -234.32K | 13.87K | -2.69M | -436.43K | -1.78M |
| EBITDA Ratio | -2,786.61% | -208.87% | -68.47% | -34.10% | -35.91% | -72.49% | -113.12% | -129.99% | -92.11% | -87.99% | -92.22% | -73.53% | -57.60% | -39.53% | -56.98% | -102.21% | -104.32% | -156.58% | -308.60% | -1,962.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.18% | -32.56% | -5.58% | -26.22% |
| Operating Income | -40.94M | -15.18M | -7.39M | -3.44M | -3.48M | -5.28M | -6.73M | -6.31M | -5.08M | -4.34M | -4.59M | -4.07M | -3.60M | -2.96M | -4.01M | -6.47M | -8.80M | -9.70M | -7.20M | -3.98M | -9.10K | -19.02K | -7.58K | -15.57K | -14.15K | -15.53K | -222.83K | -260.71K | -2.11M | -827.94K | -1.17M |
| Operating Income Ratio | -2,855.02% | -213.71% | -68.47% | -34.19% | -35.91% | -72.16% | -113.61% | -132.47% | -106.56% | -94.13% | -108.75% | -89.88% | -70.95% | -56.56% | -75.84% | -119.43% | -122.97% | -169.04% | -360.79% | -1,974.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3.32% | -25.55% | -10.59% | -17.21% |
| Total Other Income/Expenses | 835.00K | 512.00K | 119.00K | 50.00K | 30.00K | 134.00K | 29.00K | 27.00K | 154.00K | 374.61K | -1.38M | 210.00K | 170.00K | 334.00K | 0.00 | 274.00K | -274.00K | 0.00 | -385.51K | -285.99K | -2.10K | -2.10K | -41.01K | -51.50K | 0.00 | 0.00 | 12.44K | 43.40K | 895.74K | 15.91K | 920.60K |
| Income Before Tax | -40.11M | -14.67M | -7.27M | -3.39M | -3.45M | -5.14M | -6.70M | -6.16M | -4.71M | -3.68M | -5.96M | -3.86M | -3.43M | -2.84M | 0.00 | -6.20M | -9.08M | 0.00 | -8.22M | -4.27M | -11.20K | -60.03K | -59.08K | -59.08K | 0.00 | 0.00 | -3.09K | -423.98K | -2.15M | -936.57K | -435.09K |
| Income Before Tax Ratio | -2,796.79% | -206.50% | -67.36% | -33.69% | -35.60% | -70.33% | -113.12% | -129.43% | -98.77% | -79.91% | -141.24% | -85.22% | -67.60% | -54.25% | 0.00% | -114.37% | -126.79% | 0.00% | -412.08% | -2,116.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5.40% | -26.03% | -11.98% | -6.41% |
| Income Tax Expense | -2.65M | 0.00 | -119.00K | -199.00K | -177.00K | -294.00K | -29.00K | -145.00K | -371.20K | -655.14K | 1.37M | -210.66K | -109.07K | -120.78K | 24.96K | -309.74K | -245.21K | -94.68K | 1.02M | 0.00 | -86.96K | -84.85K | 41.01K | 51.50K | -250.68K | 51.50K | -942.00 | 2.10K | 2.00K | 2.60K | 2.50K |
| Net Income | -46.51M | -14.67M | -7.15M | -3.19M | -3.27M | -4.85M | -6.70M | -6.16M | -4.71M | -3.68M | -5.96M | -3.86M | -3.49M | -2.84M | -4.03M | -6.16M | -8.56M | -9.61M | -8.22M | -4.27M | 75.76K | -60.03K | -59.08K | 235.11K | -65.65K | 1.82M | -139.55K | -426.08K | -2.15M | -939.17K | -437.59K |
| Net Income Ratio | -3,243.24% | -206.50% | -66.26% | -31.71% | -33.77% | -66.31% | -113.12% | -129.43% | -98.77% | -79.91% | -141.24% | -85.22% | -68.80% | -54.25% | -76.31% | -113.71% | -119.54% | -167.39% | -412.08% | -2,116.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5.43% | -26.06% | -12.01% | -6.45% |
| EPS | -1.40 | -0.10 | -0.05 | -0.03 | -0.05 | -0.07 | -0.12 | -0.11 | -0.09 | -0.07 | -0.14 | -0.11 | -0.12 | -0.11 | -0.18 | -0.27 | -0.37 | -0.54 | -0.68 | -197.24 | 0.03 | -0.07 | -0.18 | 0.60 | -0.20 | 5.41 | -0.42 | -1.29 | -6.63 | -3.27 | -1.52 |
| EPS Diluted | -1.40 | -0.10 | -0.05 | -0.03 | -0.05 | -0.07 | -0.12 | -0.11 | -0.09 | -0.07 | -0.14 | -0.11 | -0.12 | -0.11 | -0.18 | -0.27 | -0.37 | -0.54 | -0.68 | -197.24 | 0.03 | -0.07 | -0.18 | 0.60 | -0.20 | 5.41 | -0.42 | -1.29 | -6.63 | -3.27 | -1.52 |
| Weighted Avg Shares Out | 26.76M | 142.10M | 141.99M | 103.84M | 67.60M | 67.04M | 55.16M | 55.02M | 55.01M | 54.88M | 42.68M | 34.42M | 28.62M | 25.13M | 22.96M | 22.94M | 23.03M | 17.83M | 12.05M | 21.65K | 2.36M | 804.04K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 324.73K | 287.61K | 287.61K |
| Weighted Avg Shares Out (Dil) | 26.76M | 142.10M | 141.99M | 103.84M | 67.60M | 67.04M | 55.16M | 55.02M | 55.02M | 54.88M | 42.68M | 34.42M | 28.62M | 25.13M | 22.96M | 22.94M | 23.03M | 17.83M | 12.05M | 21.65K | 2.36M | 804.04K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 324.73K | 287.61K | 287.61K |
Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights
RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering...
Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment
RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options...
The Best Penny Stock to Buy Now ZH vs CATX vs LMFA
For those who laugh in the face of extreme financial danger, the concept of acquiring the best penny stock to buy now might get the heart racing. Given this category's often rock-bottom share prices, these wildly speculative ideas command much...
Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS)
Three poster presentations from Perspective Therapeutics' scientists and collaborators explore combinations of immunotherapy and targeted alpha-particle therapy in a malignant melanoma model, 2 03Pb manufacturing, and In Vivo Distribution of Recoiled 213Bi from [225Ac]Ac-DOTATATE
IsoRay (ISR) Reports Q2 Loss, Misses Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of -100% and 56.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Isoray, Inc. (ISR) Q1 2023 Earnings Call Transcript
Isoray, Inc. (NYSE:ISR ) Q1 2023 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Thijs Spoor - CEO, Viewpoint Molecular Targeting Jonathan Hunt - CFO Conference Call Participants Mike...
Isoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022
Conference Call is Thursday, November 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Thursday, November 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT
Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT
RICHLAND, Wash. & CORALVILLE, Iowa--(BUSINESS WIRE)--Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, and Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced...
Isoray, Inc. (ISR) Q4 2022 Earnings Call Transcript
Isoray, Inc. (NYSE:ISR ) Q4 2022 Earnings Conference Call September 28, 2022 4:30 PM ET Company Participants Mark Levin - Investor Relations Lori Woods - Chief Executive Officer Thijs Spoor - Chief Executive Officer, Viewpoint Molecular Targeting Jonathan Hunt -...
IsoRay (ISR) Reports Q4 Loss, Misses Revenue Estimates
IsoRay (ISR) delivered earnings and revenue surprises of 0% and 13.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Source: https://incomestatements.info
Category: Stock Reports